This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Valgimigli, M. Articles by Ferrari, R. Search for Related Content PubMed PubMed Citation Articles by Valgimigli, M. Articles by Ferrari, R.

The additive value of tirofiban administered with the high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty

The advance trial

Marco Valgimigli, MD^*,*, Gianfranco Percoco, MD^*, Dario Barbieri, MD^*, Fabrizio Ferrari, MD^*, Gabriele Guardigli, MD^*, Giovanni Parrinello, PhD, Olga Soukhomovskaia, MD^* and Roberto Ferrari, MD, PhD^*

^* Department of Cardiology, University of Ferrara, Ferrara, Italy
Cardiovascular Research Centre, Salvatore Maugeri Foundation, IRCCS Gussago (BS), Gussago, Italy
Medical Statistics Unit, University of Brescia, Brescia, Italy

View larger version (13K): [in a new window]   Figure 1 Kaplan-Meier survival analysis: plot of proportion of cumulative survival free from primary end point events in patients treated with high-dose bolus (HDB) tirofiban (solid line) and placebo (dotted line). The difference in the incidence of events emerged soon after the procedure. At month 6, the hazard ratio was 0.51 (95% confidence interval 0.29 to 0.88, p = 0.01 by the log-rank test).

View larger version (10K): [in a new window]   Figure 2 Subgroup analysis. Hazard risk of primary end point according to the presence or absence of acute coronary syndrome as an indication to percutaneous coronary intervention or a history of diabetes. The horizontal lines indicate the 95% confidence interval.